Cargando…

Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome

AIMS/HYPOTHESIS: Diabetes is one of the cardinal features of thiamine-responsive megaloblastic anaemia (TRMA) syndrome. Current knowledge of this rare monogenic diabetes subtype is limited. We investigated the genotype, phenotype and response to thiamine (vitamin B(1)) in a cohort of individuals wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Habeb, Abdelhadi M., Flanagan, Sarah E., Zulali, Mohamed A., Abdullah, Mohamed A., Pomahačová, Renata, Boyadzhiev, Veselin, Colindres, Lesby E., Godoy, Guillermo V., Vasanthi, Thiruvengadam, Al Saif, Ramlah, Setoodeh, Aria, Haghighi, Amirreza, Haghighi, Alireza, Shaalan, Yomna, Hattersley, Andrew T., Ellard, Sian, De Franco, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449001/
https://www.ncbi.nlm.nih.gov/pubmed/29450569
http://dx.doi.org/10.1007/s00125-018-4554-x
_version_ 1783408774620381184
author Habeb, Abdelhadi M.
Flanagan, Sarah E.
Zulali, Mohamed A.
Abdullah, Mohamed A.
Pomahačová, Renata
Boyadzhiev, Veselin
Colindres, Lesby E.
Godoy, Guillermo V.
Vasanthi, Thiruvengadam
Al Saif, Ramlah
Setoodeh, Aria
Haghighi, Amirreza
Haghighi, Alireza
Shaalan, Yomna
Hattersley, Andrew T.
Ellard, Sian
De Franco, Elisa
author_facet Habeb, Abdelhadi M.
Flanagan, Sarah E.
Zulali, Mohamed A.
Abdullah, Mohamed A.
Pomahačová, Renata
Boyadzhiev, Veselin
Colindres, Lesby E.
Godoy, Guillermo V.
Vasanthi, Thiruvengadam
Al Saif, Ramlah
Setoodeh, Aria
Haghighi, Amirreza
Haghighi, Alireza
Shaalan, Yomna
Hattersley, Andrew T.
Ellard, Sian
De Franco, Elisa
author_sort Habeb, Abdelhadi M.
collection PubMed
description AIMS/HYPOTHESIS: Diabetes is one of the cardinal features of thiamine-responsive megaloblastic anaemia (TRMA) syndrome. Current knowledge of this rare monogenic diabetes subtype is limited. We investigated the genotype, phenotype and response to thiamine (vitamin B(1)) in a cohort of individuals with TRMA-related diabetes. METHODS: We studied 32 individuals with biallelic SLC19A2 mutations identified by Sanger or next generation sequencing. Clinical details were collected through a follow-up questionnaire. RESULTS: We identified 24 different mutations, of which nine are novel. The onset of the first TRMA symptom ranged from birth to 4 years (median 6 months [interquartile range, IQR 3–24]) and median age at diabetes onset was 10 months (IQR 5–27). At presentation, three individuals had isolated diabetes and 12 had asymptomatic hyperglycaemia. Follow-up data was available for 15 individuals treated with thiamine for a median 4.7 years (IQR 3–10). Four patients were able to stop insulin and seven achieved better glycaemic control on lower insulin doses. These 11 patients were significantly younger at diabetes diagnosis (p = 0.042), at genetic testing (p = 0.01) and when starting thiamine (p = 0.007) compared with the rest of the cohort. All patients treated with thiamine became transfusion-independent and adolescents achieved normal puberty. There were no additional benefits of thiamine doses >150 mg/day and no reported side effects up to 300 mg/day. CONCLUSIONS/INTERPRETATION: In TRMA syndrome, diabetes can be asymptomatic and present before the appearance of other features. Prompt recognition is essential as early treatment with thiamine can result in improved glycaemic control, with some individuals becoming insulin-independent. DATA AVAILABILITY: SLC19A2 mutation details have been deposited in the Decipher database (https://decipher.sanger.ac.uk/). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-018-4554-x) contains peer-reviewed but unedited supplementary material, which is available to authorised users.
format Online
Article
Text
id pubmed-6449001
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-64490012019-04-17 Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome Habeb, Abdelhadi M. Flanagan, Sarah E. Zulali, Mohamed A. Abdullah, Mohamed A. Pomahačová, Renata Boyadzhiev, Veselin Colindres, Lesby E. Godoy, Guillermo V. Vasanthi, Thiruvengadam Al Saif, Ramlah Setoodeh, Aria Haghighi, Amirreza Haghighi, Alireza Shaalan, Yomna Hattersley, Andrew T. Ellard, Sian De Franco, Elisa Diabetologia Article AIMS/HYPOTHESIS: Diabetes is one of the cardinal features of thiamine-responsive megaloblastic anaemia (TRMA) syndrome. Current knowledge of this rare monogenic diabetes subtype is limited. We investigated the genotype, phenotype and response to thiamine (vitamin B(1)) in a cohort of individuals with TRMA-related diabetes. METHODS: We studied 32 individuals with biallelic SLC19A2 mutations identified by Sanger or next generation sequencing. Clinical details were collected through a follow-up questionnaire. RESULTS: We identified 24 different mutations, of which nine are novel. The onset of the first TRMA symptom ranged from birth to 4 years (median 6 months [interquartile range, IQR 3–24]) and median age at diabetes onset was 10 months (IQR 5–27). At presentation, three individuals had isolated diabetes and 12 had asymptomatic hyperglycaemia. Follow-up data was available for 15 individuals treated with thiamine for a median 4.7 years (IQR 3–10). Four patients were able to stop insulin and seven achieved better glycaemic control on lower insulin doses. These 11 patients were significantly younger at diabetes diagnosis (p = 0.042), at genetic testing (p = 0.01) and when starting thiamine (p = 0.007) compared with the rest of the cohort. All patients treated with thiamine became transfusion-independent and adolescents achieved normal puberty. There were no additional benefits of thiamine doses >150 mg/day and no reported side effects up to 300 mg/day. CONCLUSIONS/INTERPRETATION: In TRMA syndrome, diabetes can be asymptomatic and present before the appearance of other features. Prompt recognition is essential as early treatment with thiamine can result in improved glycaemic control, with some individuals becoming insulin-independent. DATA AVAILABILITY: SLC19A2 mutation details have been deposited in the Decipher database (https://decipher.sanger.ac.uk/). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-018-4554-x) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer Berlin Heidelberg 2018-02-15 2018 /pmc/articles/PMC6449001/ /pubmed/29450569 http://dx.doi.org/10.1007/s00125-018-4554-x Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Habeb, Abdelhadi M.
Flanagan, Sarah E.
Zulali, Mohamed A.
Abdullah, Mohamed A.
Pomahačová, Renata
Boyadzhiev, Veselin
Colindres, Lesby E.
Godoy, Guillermo V.
Vasanthi, Thiruvengadam
Al Saif, Ramlah
Setoodeh, Aria
Haghighi, Amirreza
Haghighi, Alireza
Shaalan, Yomna
Hattersley, Andrew T.
Ellard, Sian
De Franco, Elisa
Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome
title Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome
title_full Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome
title_fullStr Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome
title_full_unstemmed Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome
title_short Pharmacogenomics in diabetes: outcomes of thiamine therapy in TRMA syndrome
title_sort pharmacogenomics in diabetes: outcomes of thiamine therapy in trma syndrome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449001/
https://www.ncbi.nlm.nih.gov/pubmed/29450569
http://dx.doi.org/10.1007/s00125-018-4554-x
work_keys_str_mv AT habebabdelhadim pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT flanagansarahe pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT zulalimohameda pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT abdullahmohameda pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT pomahacovarenata pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT boyadzhievveselin pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT colindreslesbye pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT godoyguillermov pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT vasanthithiruvengadam pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT alsaiframlah pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT setoodeharia pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT haghighiamirreza pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT haghighialireza pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT shaalanyomna pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT hattersleyandrewt pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT ellardsian pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome
AT defrancoelisa pharmacogenomicsindiabetesoutcomesofthiaminetherapyintrmasyndrome